GO:0055093 response to hyperoxia: Genes and Methods

GO:0055093, response to hyperoxia, is a biological_process Gene Ontology term defined as any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating increased oxygen tension. In practical terms, it captures everything a biological system does when oxygen levels rise above its normal physiological set point, from immediate ventilatory reflexes to long-lasting transcriptional and epigenetic remodeling. Because oxygen is both essential and toxic, the response to hyperoxia sits at the intersection of redox biology, mitochondrial function, inflammation and cell survival. Researchers care about GO:0055093 because hyperoxia is a common clinical exposure (supplemental oxygen, hyperbaric therapy, cardiopulmonary bypass) and an experimental variable that reshapes disease phenotypes. Studies in the brain show that chronic hyperoxia produces a transcriptional and metabolic response distinct from chronic hypoxia, indicating that the two oxygen extremes are not mirror images. In the neonatal lung, the hyperoxic response is sexually dimorphic at the epigenetic level, which has direct implications for bronchopulmonary dysplasia and other oxygen-related neonatal diseases. In the vasculature, hyperoxia reprograms endothelial cells in an organ-specific manner, altering their subsequent hypoxia response. At the organism level, the response to hyperoxia includes measurable physiological outputs such as ventilatory changes during isocapnic hyperoxia and retinal blood flow and oxygen delivery changes during carotid occlusion. At the cellular level, it includes stress pathways such as the unfolded protein response, which can be exploited therapeutically, for example to resensitize chemoresistant glioblastoma cells to temozolomide. This article summarizes the ontology definition, the major biological stages, the key genes and proteins, disease links, and the CRISPR and multi-omics methods used to study GO:0055093.

In our own words, GO:0055093 response to hyperoxia is the collection of cellular and organismal processes triggered when oxygen tension rises above the normal physiological range. It is not a single pathway but a coordinated program that can include changes in gene expression, enzyme production, secretion, movement and metabolic activity. The term is agnostic about whether the outcome is protective, adaptive or injurious; it simply requires that the change in state or activity is caused by increased oxygen tension. Synonyms include response to hyperoxic stress and response to increased oxygen tension.

GO:0055093 matters because oxygen tension is a controllable and clinically pervasive variable, and the biological response to hyperoxia determines outcomes in neonatal care, neurocritical care, ophthalmology and oncology. Understanding this response at the gene and pathway level allows researchers to separate adaptive protection from oxygen toxicity and to identify targets that can be modulated with CRISPR-based models.

The following genes and proteins are representative participants or readouts of the response to hyperoxia, based on the cited literature; the list is not exhaustive and is intended to guide experimental design.

The response to hyperoxia is regulated at multiple levels. Transcriptional control is mediated by oxygen-sensitive factors such as HIF1A and EPAS1, whose activity and target gene sets are reshaped when oxygen tension rises, and this reshaping is organ-specific in endothelial cells. Epigenetic regulation is prominent in the neonatal lung, where DNA methylation and related chromatin marks change after hyperoxia in a sexually dimorphic manner, implicating DNMT and TET family enzymes. Stress-responsive translational and proteostatic control is exerted through the unfolded protein response, including ATF4, DDIT3, HSPA5 and XBP1, which can determine whether hyperoxia sensitizes or protects cells. Physiologically, the response is also regulated by systemic factors such as blood flow and oxygen delivery, as shown by retinal and ventilatory studies. Together, these layers create a tunable, context-dependent program rather than a fixed linear pathway.

Supplemental oxygen in neonates exposes the developing lung to hyperoxia, and the epigenetic response to hyperoxia in the neonatal lung is sexually dimorphic, which may contribute to differences in disease susceptibility between males and females. This makes GO:0055093 directly relevant to bronchopulmonary dysplasia and other oxygen-related neonatal lung conditions, and it motivates studies that combine oxygen exposure with epigenetic profiling.

The retina is highly sensitive to oxygen tension. Hyperoxia changes retinal oxygen delivery and metabolism during bilateral common carotid artery occlusion in rats, and retinal blood flow responses to hyperoxia can be measured non-invasively in humans with en face Doppler optical coherence tomography. These findings link GO:0055093 to retinal ischemic disease and to the vascular biology of oxygen therapy.

In chemoresistant glioblastoma cells, hyperoxia resensitizes the cells to temozolomide through the unfolded protein response, demonstrating that the hyperoxia response can be therapeutically exploited. This connects GO:0055093 to cancer stress biology and suggests that oxygen tension and proteostasis pathways should be considered together in treatment design.

Comparative studies of chronic hypoxia and hyperoxia in the brain show that the two conditions produce distinct responses, so hyperoxia should not be treated as a simple opposite of hypoxia. This has implications for neurocritical care and for interpreting oxygen-related transcriptional signatures in neurological disease models.

RNA-seq and epigenomic profiling are central to mapping GO:0055093. Comparative brain studies used transcriptomic approaches to distinguish chronic hyperoxia from chronic hypoxia, and neonatal lung studies used epigenetic profiling to reveal sexually dimorphic DNA methylation changes after hyperoxia. Endothelial reprogramming by hyperoxia has also been characterized with gene expression profiling across organs.

Because GO:0055093 includes organism-level changes, physiological measurements are essential. Ventilatory responses to isocapnic hyperoxia quantify the respiratory output, while retinal oxygen delivery and metabolism can be assessed during carotid occlusion in rats. En face Doppler optical coherence tomography measures retinal blood flow responses to hyperoxia in humans.

Unfolded protein response markers such as ATF4, DDIT3, HSPA5 and XBP1 can be measured by qPCR, immunoblotting and reporter assays to determine how hyperoxia engages proteostatic stress, as shown in glioblastoma chemoresistance studies. These assays complement viability and drug-response measurements.

Genome-wide CRISPR knockout or activation screens performed under hyperoxia versus normoxia can identify genes that are required for or that modify the response to hyperoxia. Hits can then be prioritized with bioinformatics integration of transcriptomic, epigenomic and pathway data from the cited studies.

Researchers studying response to hyperoxia-related genes often need to determine whether a candidate gene is causally involved in the cellular or organismal response to elevated oxygen tension, rather than merely correlated with it. Establishing causality requires precise, reproducible genome engineering across knockout, point-mutation, knock-in and overexpression formats, ideally combined with unbiased screening and bioinformatic prioritization.

GO:0055093 response to hyperoxia is a distinct, multi-layered biological process that spans oxygen sensing, transcriptional and epigenetic reprogramming, stress pathway activation and physiological outputs such as ventilation and retinal blood flow. It is clinically relevant to neonatal lung disease, retinal ischemia, brain responses to oxygen extremes and cancer chemoresistance. Because the response is organ-specific and sexually dimorphic, careful model selection and causal perturbation are essential. CRISPR-based knockout, point-mutation, knock-in and overexpression models, combined with library screening and bioinformatics, provide a rigorous path to identify and validate the genes that govern this process.